KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Change in Accured Expenses (2016 - 2025)

Resmed (RMD) has disclosed Change in Accured Expenses for 17 consecutive years, with $10.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 152.25% year-over-year to $10.6 million, compared with a TTM value of $130.5 million through Dec 2025, down 4.25%, and an annual FY2025 reading of $91.0 million, down 25.49% over the prior year.
  • Change in Accured Expenses was $10.6 million for Q4 2025 at Resmed, up from $7.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $257.5 million in Q1 2021 and bottomed at -$293.3 million in Q3 2021.
  • Average Change in Accured Expenses over 5 years is $16.3 million, with a median of $9.3 million recorded in 2022.
  • Peak annual rise in Change in Accured Expenses hit 36862.42% in 2024, while the deepest fall reached 2399.02% in 2024.
  • Year by year, Change in Accured Expenses stood at -$12.4 million in 2021, then plummeted by 39.38% to -$17.3 million in 2022, then tumbled by 99.02% to -$34.4 million in 2023, then surged by 112.28% to $4.2 million in 2024, then skyrocketed by 152.25% to $10.6 million in 2025.
  • Business Quant data shows Change in Accured Expenses for RMD at $10.6 million in Q4 2025, $7.6 million in Q3 2025, and $49.1 million in Q2 2025.